FDA allows use of peramivir in some H1N1 flu patients

The FDA has issued an emergency-use authorization that allows doctors to administer peramivir, an antiviral drug developed by BioCryst Pharmaceuticals, in patients with H1N1 influenza. The approval limits the use of the product to patients who do not respond to Tamiflu or Relenza.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ